Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 11/20 | 0.43 |
| ▸ | JAK2 | O60674 | 10/20 | 0.43 |
| ▸ | JAK1 | P23458 | 9/20 | 0.43 |
| ▸ | TYK2 | P29597 | 5/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754208 | 1.00 | EIF2AK4 (0.45) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL22544463 | 0.94 | JAK2 (0.43) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL22544657 | 0.89 | EIF2AK4 (0.44) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL22544570 | 0.87 | LRRK2 (0.45) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL29754209 | 0.87 | LRRK2 (0.45) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL22544652 | 0.82 | JAK2 (0.44) | EIF2AK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL22097656 | 0.81 | JAK3 (0.56) | JAK3JAK2JAK1TYK2MAP3K7 | |
| SCHEMBL22529468 | 0.81 | TBK1 (0.43) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL29754214 | 0.81 | TBK1 (0.43) | JAK3JAK2JAK1TYK2LRRK2 | |
| SCHEMBL27275032 | 0.81 | TBK1 (0.44) | JAK3JAK2JAK1TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| WO-2020207414-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020206588-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | EIF2AK4 774/4885JAK3 1/4885JAK2 3/4885 |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | EIF2AK4 780/4885JAK3 1/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.